Ionis Pharmaceuticals Inc (NASDAQ:IONS) CFO Elizabeth L. Hougen sold 2,724 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $51.76, for a total value of $140,994.24. Following the sale, the chief financial officer now directly owns 17,224 shares of the company’s stock, valued at $891,514.24. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Ionis Pharmaceuticals Inc (IONS) traded down $0.72 during trading on Friday, hitting $46.75. The company’s stock had a trading volume of 1,895,169 shares, compared to its average volume of 1,010,000. Ionis Pharmaceuticals Inc has a one year low of $37.26 and a one year high of $65.51. The stock has a market cap of $5,830.00, a price-to-earnings ratio of 333.93 and a beta of 2.53. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50.
Several equities analysts have issued reports on the company. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 target price on the stock in a research report on Friday, October 27th. BidaskClub upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, December 7th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. BMO Capital Markets boosted their target price on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. Finally, Morgan Stanley upped their price target on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 8th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $50.76.
Institutional investors have recently modified their holdings of the business. Rothschild Asset Management Inc. lifted its stake in shares of Ionis Pharmaceuticals by 10.8% during the 3rd quarter. Rothschild Asset Management Inc. now owns 281,068 shares of the company’s stock worth $14,250,000 after purchasing an additional 27,426 shares during the period. Bank of Nova Scotia purchased a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth $1,526,000. 361 Capital LLC purchased a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth $1,596,000. GSA Capital Partners LLP acquired a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth $1,096,000. Finally, Candriam Luxembourg S.C.A. increased its holdings in shares of Ionis Pharmaceuticals by 30.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 143,000 shares of the company’s stock worth $7,250,000 after buying an additional 33,000 shares during the last quarter. 91.44% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Ionis Pharmaceuticals Inc (IONS) CFO Sells $140,994.24 in Stock” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/02/12/ionis-pharmaceuticals-inc-ions-cfo-sells-140994-24-in-stock.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.